Key points are not available for this paper at this time.
Overall, genetic testing should be offered in most patients with ovarian cancer to identify mutations in HRR genes and determine the population that would be susceptible to poly ADP ribose polymerase (PARP) inhibitors.
Andrikopoulou et al. (Thu,) studied this question.